29 January 2025 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Although rare reports describe discharge to be possible within 48 hours for patients undergoing autologous breast reconstruction, average length of stay remains around 3 days. This study aimed to demonstrate that patients can be safely discharged within 1 day after deep inferior epigastric perforator (DIEP) flap breast reconstruction. A retrospective review was performed of patients who underwent free flap breast reconstruction by a single surgeon from November 2021 to May 2024. Demographics, operative details, opioid ingestion, length of stay, and postoperative complications were reviewed to assess safety of discharge in 24 hours. One hundred sixty-four DIEP flaps were performed on 119 patients. Average length of stay was 1.5 days (SD 0.7 days), with 67 (56.3%) patients discharged on postoperative day 1 (POD1) and 52 (43.7%) discharged after POD1. Of those discharged on POD1, 13 (19.4%) went home in <24 hours. Comparing patients discharged on POD1 to those discharged after POD1, there were statistically significant differences in reconstruction laterality (76.1% vs 44.2% unilateral, p<0.001), operative time (341.0 vs 439.1 minutes, p<0.001), and opioid ingestion on POD1 (4.2 IV morphine milligram equivalents [MME] vs 11.3 MME, p<0.001). Common complications included abdominal wound dehiscence (10.1%), abdominal seroma (5.0%), breast wound dehiscence (4.9%), and breast mastectomy flap necrosis (3.0%). Seventy-six (63.9%) patients had no complications. Overall success rate of flap reconstruction was 100%. Collaboration among surgery, anesthesia, and dedicated nursing teams allow 23-hour observation or outpatient DIEP reconstruction to be safe and feasible. By attaining equivalency with implant-based reconstruction, access to flap reconstruction can be extended to more patients.
5 November 2025 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Drainless tissue expansion has been reported possible, but lacking is a description of the associated demands and implementation. This study describes expectations regarding follow-up frequency, aspiration volumes, and how experiences differ based on reconstruction timing. A retrospective review was performed of patients who underwent prepectoral dual-port tissue expander (TE) placement from February 2023 to December 2024. Medical history, intraoperative details, complications, and periprosthetic aspiration volumes were collected. Sixty-six patients making up 94 breasts were included. Average days to point of no aspiration was 21.7 (SD 9.2 days), with an average of 5.5 aspirations (SD 1.9 aspirations). After the first 2 aspirations, percentage of breasts requiring aspirations dropped; 85.1% of breasts required at least 4 aspirations, 44.7% required at least 6%, and 7.4% required at least 8. Less than 50% of breasts required aspirations after 20 days, and less than 20% required aspirations after 30 days. Average drainage per breast during the first three aspirations was 141.4, 133.0, and 123.6 mLs, respectively, and tapered with subsequent aspirations. Compared to early interval-staged reconstruction, immediate reconstruction had greater total drainage (350.7 mLs vs 816.2 mLs, p<0.001) and average drainage per aspiration (80.7 vs 128.4 mLs, p<0.001). Drainless breast reconstruction is possible with an equivalent safety profile to the standard approach utilizing drains. This study provides a better understanding of the expected frequency of aspiration sessions and volumes removed during visits. Further, the results provide support for its integration in TE reconstruction with a low rate of infection.
15 September 2026 in Annals of Plastic Surgery
Background: Corticosteroid injections (CSIs) have demonstrated efficacy in reducing pain and improving function for patients with arthritic and inflammatory pathology in the upper extremity. However, reports remain rare regarding the association of CSIs in the hand and postoperative complications. The purpose of this study was to assess the risk of postoperative complications after small joint arthroplasty and arthrodesis in patients who received preoperative CSIs in that joint before surgery. Materials and Methods: A retrospective review was performed of patients who underwent arthrodesis or arthroplasty of the distal interphalangeal (DIP) joint, proximal interphalangeal (PIP) joint, metacarpophalangeal (MP) joint, or thumb interphalangeal (IP) joint from January 2009 to December 2023. Variables collected included patient demographics, medical history, operative details, CSI history, and complications. The relationship between patient factors, CSI history, and postoperative complications was assessed. Results: A total of 192 joints in 115 patients were included in the analysis. Seventy-two (37.5%) small joints underwent arthroplasty, while 120 (62.5%) received arthrodesis. Twenty (10.4%) small joints received CSIs before operative management, and 9 (4.7%) received CSIs within 6 months of surgery. A total of 50 (26.0%) joints experienced complications, with 3 (1.6%) joints experiencing surgical site infections and 6 (3.1%) with nonunion. Analyses did not suggest a higher risk for complications in patients who received CSIs in the hand before arthroplasty or arthrodesis. Conclusions: CSIs within 6 months of hand arthrodesis or arthroplasty did not result in significantly higher complication rates, suggesting that CSIs can be performed safely before operative management of small joint arthritis.